TY - JOUR
T1 - Development of Oncolytic Virus Immunotherapy to Improve the Immunosuppressive Microenvironment in Pancreatic Cancer
AU - Suemori, Kanto
AU - Tazawa, Hiroshi
AU - Yamada, Motohiko
AU - Okada, Naohiro
AU - Kikuchi, Satoru
AU - Kuroda, Shinji
AU - Noma, Kazuhiro
AU - Urata, Yasuo
AU - Kagawa, Shunsuke
AU - Fujiwara, Toshiyoshi
PY - 2025/5/1
Y1 - 2025/5/1
N2 - Immunotherapy resistance in pancreatic ductal adenocarcinoma(PDAC)limits treatment outcomes; therefore, improving the immunosuppressive microenvironment is important for PDAC treatment. We developed an oncolytic adenovirus, OBP-702, carrying the tumor suppressor gene p53, and report its therapeutic potential to induce cytopathic effects and activate antitumor immunity via p53 induction. In the present study, we investigated the therapeutic potential of epigenetic modulators in oncolytic viral immunotherapy combined with a dendritic cell vaccine.
AB - Immunotherapy resistance in pancreatic ductal adenocarcinoma(PDAC)limits treatment outcomes; therefore, improving the immunosuppressive microenvironment is important for PDAC treatment. We developed an oncolytic adenovirus, OBP-702, carrying the tumor suppressor gene p53, and report its therapeutic potential to induce cytopathic effects and activate antitumor immunity via p53 induction. In the present study, we investigated the therapeutic potential of epigenetic modulators in oncolytic viral immunotherapy combined with a dendritic cell vaccine.
UR - http://www.scopus.com/inward/record.url?scp=105006949773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105006949773&partnerID=8YFLogxK
M3 - Article
C2 - 40420372
AN - SCOPUS:105006949773
SN - 0385-0684
VL - 52
SP - 399
EP - 401
JO - Gan to kagaku ryoho. Cancer & chemotherapy
JF - Gan to kagaku ryoho. Cancer & chemotherapy
IS - 5
ER -
